The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.

[1]  D. Wagner,et al.  Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. , 2011, Cancer research.

[2]  L. Borsig.  Antimetastatic activities of heparins and modified heparins. Experimental evidence. , 2010, Thrombosis research.

[3]  P. Reitsma,et al.  Mechanisms of heparin induced anti-cancer activity in experimental cancer models. , 2007, Critical reviews in oncology/hematology.

[4]  H. Imamura,et al.  Poor prognosis associated with thrombocytosis in patients with gastric cancer , 2002, Annals of Surgical Oncology.

[5]  K. Honn,et al.  Platelets and cancer metastasis: A causal relationship? , 1992, Cancer and Metastasis Reviews.

[6]  F. Keil,et al.  Thrombocytosis in gynecologic malignancies. , 2004, Anticancer research.

[7]  B. Karlan,et al.  The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. , 2004, Gynecologic oncology.

[8]  N. Milman,et al.  Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. , 2003, Oncology reports.

[9]  R. Salgado,et al.  Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. , 2002, Clinical breast cancer.

[10]  R. Schwarz,et al.  Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. , 2001, Hepato-gastroenterology.

[11]  C. V. van Noorden,et al.  The complex effects of heparins on cancer progression and metastasis in experimental studies. , 2001, Pharmacological reviews.

[12]  P. Heller,et al.  The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. , 2000, Gynecologic oncology.

[13]  M. Raderer,et al.  Inhibition of metastases by anticoagulants. , 1999, Journal of the National Cancer Institute.

[14]  D. Geva,et al.  Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. , 1998, European journal of gynaecological oncology.

[15]  J W van Wersch,et al.  Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. , 1997, European journal of obstetrics, gynecology, and reproductive biology.

[16]  J. Nam,et al.  Significance of Thrombocytosis in Patients with Epithelial Ovarian Cancer , 1997 .

[17]  G. Tuszynski,et al.  Expression of Thrombospondin-1 in Cancer: A Role in Tumor Progression , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[18]  H. D. de Bruijn,et al.  Higher levels of interleukin‐6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts , 1995, Cancer.

[19]  N. Bander,et al.  High IL‐6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer , 1993, British journal of haematology.

[20]  M. Takagi,et al.  Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. , 1991, Blood.

[21]  G. Tuszynski,et al.  Thrombospondin, a potentiator of tumor cell metastasis. , 1987, Cancer research.

[22]  S. Karpatkin,et al.  Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. , 1984, Cancer research.

[23]  S. Karpatkin,et al.  ROLE OF PLATELETS IN TUMOR CELL METASTASES , 1981, Annals of internal medicine.